Teva- Pharmaceutical Industries Debt to Equity

The latest debt-to-equity ratio for TEVA is 2.18. That is above the Healthcare sector average of 0.3. Investors often review this figure alongside Teva- Pharmaceutical Industries's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, TEVA currently prints 2.18 for debt-to-equity ratio, while the sector average sits near 0.3. That is roughly 623.0% above the sector mean. Large gaps often invite a closer look at Teva- Pharmaceutical Industries's growth, margins, and balance sheet.

A debt-to-equity ratio of 2.18 for Teva- Pharmaceutical Industries is not 'good' or 'bad' on its own. Compare it with the peer average (0.3) and with TEVA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting TEVA's debt-to-equity ratio (2.18), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Teva- Pharmaceutical Industries's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.